These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38445950)

  • 1. Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial.
    Čelutkienė J; Čerlinskaitė-Bajorė K; Cotter G; Edwards C; Adamo M; Arrigo M; Barros M; Biegus J; Chioncel O; Cohen-Solal A; Damasceno A; Diaz R; Filippatos G; Gayat E; Kimmoun A; Léopold V; Metra M; Novosadova M; Pagnesi M; Pang PS; Ponikowski P; Saidu H; Sliwa K; Takagi K; Ter Maaten JM; Tomasoni D; Lam CSP; Voors AA; Mebazaa A; Davison B
    Circ Heart Fail; 2024 Apr; 17(4):e011221. PubMed ID: 38445950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.
    Mebazaa A; Davison B; Chioncel O; Cohen-Solal A; Diaz R; Filippatos G; Metra M; Ponikowski P; Sliwa K; Voors AA; Edwards C; Novosadova M; Takagi K; Damasceno A; Saidu H; Gayat E; Pang PS; Celutkiene J; Cotter G
    Lancet; 2022 Dec; 400(10367):1938-1952. PubMed ID: 36356631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Felker GM; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Mark DB; Piña IL; Passmore G; Whellan DJ; Yang H; Cooper LS; Leifer ES; Desvigne-Nickens P; O'Connor CM
    JAMA; 2017 Aug; 318(8):713-720. PubMed ID: 28829876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial.
    Cotter G; Deniau B; Davison B; Edwards C; Adamo M; Arrigo M; Barros M; Biegus J; Celutkiene J; Cerlinskaite-Bajore K; Chioncel O; Cohen-Solal A; Damasceno A; Diaz R; Filippatos G; Gayat E; Kimmoun A; Lam CSP; Metra M; Novosadova M; Pang PS; Pagnesi M; Ponikowski P; Saidu H; Sliwa K; Takagi K; Ter Maaten JM; Tomasoni D; Voors A; Mebazaa A
    JAMA Cardiol; 2024 Feb; 9(2):114-124. PubMed ID: 38150260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial.
    Tomasoni D; Davison B; Adamo M; Pagnesi M; Mebazaa A; Edwards C; Arrigo M; Barros M; Biegus J; Čelutkienė J; Čerlinskaitė-Bajorė K; Chioncel O; Cohen-Solal A; Damasceno A; Diaz R; Filippatos G; Gayat E; Kimmoun A; Lam CSP; Novosadova M; Pang PS; Ponikowski P; Saidu H; Sliwa K; Takagi K; Maaten JMT; Voors A; Cotter G; Metra M
    J Card Fail; 2024 Apr; 30(4):525-537. PubMed ID: 37820896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
    Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
    Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction.
    Pagnesi M; Metra M; Cohen-Solal A; Edwards C; Adamo M; Tomasoni D; Lam CSP; Chioncel O; Diaz R; Filippatos G; Ponikowski P; Sliwa K; Voors AA; Kimmoun A; Novosadova M; Takagi K; Barros M; Damasceno A; Saidu H; Gayat E; Pang PS; Celutkiene J; Cotter G; Mebazaa A; Davison B
    J Am Coll Cardiol; 2023 Jun; 81(22):2131-2144. PubMed ID: 37257948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction.
    Daubert MA; Yow E; Barnhart HX; Piña IL; Ahmad T; Leifer E; Cooper L; Desvigne-Nickens P; Fiuzat M; Adams K; Ezekowitz J; Whellan DJ; Januzzi JL; O'Connor CM; Felker GM
    J Am Heart Assoc; 2021 May; 10(10):e019712. PubMed ID: 33955231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
    Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
    Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
    Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
    Kimmoun A; Cotter G; Davison B; Takagi K; Addad F; Celutkiene J; Chioncel O; Solal AC; Diaz R; Damasceno A; Duengen HD; Filippatos G; Goncalvesova E; Merai I; Metra M; Ponikowski P; Privalov D; Sliwa K; Sani MU; Voors AA; Shogenov Z; Mebazaa A
    Eur J Heart Fail; 2019 Nov; 21(11):1459-1467. PubMed ID: 31423712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
    Ehteshami-Afshar S; Mooney L; Dewan P; Desai AS; Lang NN; Lefkowitz MP; Petrie MC; Rizkala AR; Rouleau JL; Solomon SD; Swedberg K; Shi VC; Zile MR; Packer M; McMurray JJV; Jhund PS; Hawkins NM
    J Am Heart Assoc; 2021 Feb; 10(4):e019238. PubMed ID: 33522249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial.
    Adamo M; Pagnesi M; Mebazaa A; Davison B; Edwards C; Tomasoni D; Arrigo M; Barros M; Biegus J; Celutkiene J; Čerlinskaitė-Bajorė K; Chioncel O; Cohen-Solal A; Damasceno A; Diaz R; Filippatos G; Gayat E; Kimmoun A; Lam CSP; Novosadova M; Pang PS; Ponikowski P; Saidu H; Sliwa K; Takagi K; Ter Maaten JM; Voors A; Cotter G; Metra M
    Eur Heart J; 2023 Aug; 44(31):2947-2962. PubMed ID: 37217188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity and Serial NT-proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE-IT Trial.
    Parcha V; Patel N; Kalra R; Suri SS; Arora G; Wang TJ; Arora P
    J Am Heart Assoc; 2021 Apr; 10(7):e018689. PubMed ID: 33754794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
    Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
    Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
    Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
    JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.